<DOC>
	<DOCNO>NCT00687843</DOCNO>
	<brief_summary>Since uncertain efficacy combination therapy PSK TS-1 gastric cancer , study , compare efficacy safety postoperative adjuvant therapy use TS-1 TS-1+PSK stage II III gastric cancer patient .</brief_summary>
	<brief_title>Study TS-1 TS-1 + PSK Gastric Cancer Patients</brief_title>
	<detailed_description>TS-1 oral anticancer drug approve Japan consist tegafur ( pro-drug fluorouracil , 5-FU ) , gimeracil oteracil potassium . The response rate TS-1 untreated advanced gastric cancer patient 44.6 % late phase II study . In 2007 , efficacy adjuvant therapy use TS-1 resect gastric cancer patient demonstrate ACTS-GC study group conduct Japan . PSK oral anticancer drug approve Japan consist protein-bound polysaccharide extract mycelium Trametes ( Coriolus ) versicolor , kind mushroom . Even though survival benefit PSK combination adjuvant chemotherapy use 5-FU tegafur postoperative gastric cancer patient already demonstrate , uncertain efficacy combination therapy PSK TS-1 gastric cancer . In study , compare efficacy safety postoperative adjuvant therapy use TS-1 TS-1+PSK stage II III gastric cancer patient .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Patient pathologically confirm gastric cancer Patient receive surgery D2 lymph node dissection whose final curability surgical resection grade A B Patient whose final stage II ( except T1 ) , IIIA , IIIB Patient without liver , peritoneal distant metastasis , negative peritoneal cytological diagnosis Patient whose age registration range 20 80 year old Patient receive preoperative therapy include radiotherapy , chemotherapy immunotherapy Patient receive surgery gastric cancer within six week registration , judge capable oral administration Patient serious concurrent complication , satisfies follow criterion White blood cell count : &gt; LLN &gt; 4,000 /mm3 Platelet count : &gt; 100,000 /mm3 Serum total bilirubin : &lt; 1.5 mg/dL Serum AST ( GOT ) , ALT ( GPT ) : &lt; 2.5 * ULN Serum creatinine : &lt; ULN Patient receive explanation study assent document , give write informed consent participate study Patient metachronous synchronous multicancer Patient contraindicate TS1 Patient require continuous use flucytosine , phenytoin warfarin potassium Patient experience serious drug allergy grade 3 past Patient serious complication include paralysis intestine , ileus , interstitial pneumonitis , fibroid lung , uncontrollable diabetes mellitus , heart insufficiency , renal insufficiency hepatic insufficiency Patient diarrhea ( watery stool ) Patient pregnant lactation , wish become pregnant study Male patient intend make someone pregnant study Patient HIV positive Patient judge inappropriate subject study principal investigator doctor charge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>TS-1</keyword>
	<keyword>PSK</keyword>
	<keyword>Relapse-free survival</keyword>
</DOC>